Mutations in the essential FAS II β-hydroxyacyl ACP dehydratase complex confer resistance to thiacetazone in Mycobacterium tuberculosis and Mycobacterium kansasii

Molecular Microbiology

Volumn 86, Issue 3, 2012, Pages 568-579

  Belardinelli, Juan M ^a   Morbidoni, Héctor R ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; BACTERIAL PROTEIN; CHROMOSOME PROTEIN; FATTY ACID SYNTHASE; MYCOLIC ACID; THIOACETAZONE; TYPE II FATTY ACID SYNTHASE BETA HYDROXYACYL ACP DEHYDRATASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATION; BACTERIUM MUTANT; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ETHA GENE; FATTY ACID SYNTHASE GENE; FATTY ACID SYNTHESIS; GENE MUTATION; HADABC GENE; MINIMUM INHIBITORY CONCENTRATION; MMAA4 GENE; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPERON; PRIORITY JOURNAL; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; ENOYL-COA HYDRATASE; FATTY ACID SYNTHETASE COMPLEX, TYPE II; MOLECULAR SEQUENCE DATA; MUTATION; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; MYCOLIC ACIDS; OPERON; SEQUENCE ALIGNMENT; THIOACETAZONE;

MYCOBACTERIUM BOVIS; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS;

EID: 84868125770     PISSN: 0950382X     EISSN: 13652958     Source Type: Journal    
DOI: 10.1111/mmi.12005     Document Type: Article

References (28)

1. Abate, G., Koivula, T., and Hoffner, S.E. (2002) In vitro activity of thiacetazone on mycobacterial species belonging to the Mycobacterium tuberculosis complex. Int J Tuberc Lung Dis 6: 933-935.
2. Ainsa, J.A., Blokpoel, M.C., Otal, I., Young, D.B., De Smet, K.A., and Martin, C. (1998) Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol 180: 5836-5843.
3. Alahari, A., Trivelli, X., Guerardel, Y., Dover, L.G., Besra, G.S., Sacchettini, J.C., etal. (2007) Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS ONE 2: e1343.
4. Alahari, A., Alibaud, L., Trivelli, X., Gupta, R., Lamichhane, G., Reynolds, R.C., etal. (2009) Mycolic acid methyltransferase, MmaA4, is necessary for thiacetazone susceptibility in Mycobacterium tuberculosis. Mol Microbiol 71: 1263-1277.
5. Andries, K., Verhasselt, P., Guillemont, J., Gohlmann, H.W., Neefs, J.M., Winkler, H., etal. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
6. Cantaloube, S., Veyron-Churlet, R., Haddache, N., Daffé, M., and Zerbib, D. (2011) The Mycobacterium tuberculosis FAS-II dehydratases and methyltransferases define the specificity of the mycolic acid elongation complexes. PLoS ONE 6: e29564.
7. Cavanagh, P., and McPherson, K. (1969) The thiacetazone sensitivity of Mycobacterium tuberculosis. J Med Microbiol 2: 237-242.
8. DeBarber, A.E., Mdluli, K., Bosman, M., Bekker, L.G., and Barry, C.E., III (2000) Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA 97: 9677-9682.
9. Dover, L.G., Alahari, A., Gratraud, P., Gomes, J.M., Bhowruth, V., Reynolds, R.C., etal. (2007) EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrob Agents Chemother 51: 1055-1063.
10. Dye, C., Williams, B.G., Espinal, M.A., and Raviglione, M.C. (2002) Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295: 2042-2046.
11. Fegan, D. (1994) Thiacetazone - use with care. Trans R Soc Trop Med Hyg 88: 714.
12. Fegan, D. (1995) Use of thiacetazone. Lancet 345: 63.
13. Fegan, D., and Glennon, J. (1991) Cutaneous sensitivity to thiacetazone. Lancet 337: 1036.
14. Grau, T., Selchow, P., Tigges, M., Burri, R., Gitzinger, M., Bottger, E.C., etal. (2012) Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 1142-1145.
15. Heym, B., Alzari, P.M., Honore, N., and Cole, S.T. (1995) Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 15: 235-245.
16. Huff, J., Czyz, A., Landick, R., and Niederweis, M. (2010) Taking phage integration to the next level as a genetic tool for mycobacteria. Gene 468: 8-19.
17. Mitchison, D.A. (1968) Natural sensitivity of M. tuberculosis to thiacetazone. Tubercle 49: Suppl-46.
18. Morlock, G.P., Crawford, J.T., Butler, W.R., Brim, S.E., Sikes, D., Mazurek, G.H., etal. (2000) Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 44: 2291-2295.
19. Pasca, M.R., Guglierame, P., Arcesi, F., Bellinzoni, M., De, R.E., and Riccardi, G. (2004) Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Chemother 48: 3175-3178.
20. Sacco, E., Covarrubias, A.S., O'Hare, H.M., Carroll, P., Eynard, N., Jones, T.A., etal. (2007) The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis. Proc Natl Acad Sci USA 104: 14628-14633.
21. Sassetti, C.M., Boyd, D.H., and Rubin, E.J. (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84.
22. Silcox, V.A., and David, H.L. (1971) Differential identification of Mycobacterium kansasii and Mycobacterium marinum. Appl Microbiol 21: 327-334.
23. Silva, P.E., Bigi, F., Santangelo, M.P., Romano, M.I., Martin, C., Cataldi, A., and Ainsa, J.A. (2001) Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis. Antimicrob Agents Chemother 45: 800-804.
24. Singh, M., Jadaun, G.P., Ramdas, Srivastava, K., Chauhan, V., Mishra, R., etal. (2011) Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J Med Res 133: 535-540.
25. Takiff, H.E., Cimino, M., Musso, M.C., Weisbrod, T., Martinez, R., Delgado, M.B., etal. (1996) Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci USA 93: 362-366.
26. Veyron-Churlet, R., Bigot, S., Guerrini, O., Verdoux, S., Malaga, W., Daffé, M., and Zerbib, D. (2005) The biosynthesis of mycolic acids in Mycobacterium tuberculosis relies on multiple specialized elongation complexes interconnected by specific protein-protein interactions. J Mol Biol 353: 847-858.
27. Vilcheze, C., Morbidoni, H.R., Weisbrod, T.R., Iwamoto, H., Kuo, M., Sacchettini, J.C., and Jacobs, W.R., Jr (2000) Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol 182: 4059-4067.
28. Weber, W., Schoenmakers, R., Keller, B., Gitzinger, M., Grau, T., Daoud-El, B.M., etal. (2008) A synthetic mammalian gene circuit reveals antituberculosis compounds. Proc Natl Acad Sci USA 105: 9994-9998.